The Platelet – Thrombosis and Beyond

• References

• 1 Langer HF, Gawaz M. Platelet-vessel wall interactions in atherosclerotic disease. Thromb Haemost 2008; 99: 480-486.
• 2 Nachman RL, Rafii S. Platelets, petechiae, and preservation of the vascular wall. N Engl J Med 2008; 359: 1261-1270.
• 3 Geisler T, Grass D, Bigalke B. et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 2008; 6: 54-61.
• 4 Serebruany VL. Viewpoint: reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel. Thromb Haemost 2012; 108: 1024-1027.
• 5 Serebruany VL, Atar D. Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials–common patterns in TRITON, RECORD, and PLATO? Thromb Haemost 2012; 108: 412-414.
• 6 Verheugt FW. Outcomes of positive randomised controlled clinical trials: double-blind or double vision? Editorial on Serebruany, Atar: 'Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials–common patterns in TRITON, RECORD, and PLATO?' (Thromb Haemost 2012; 108.3). Thromb Haemost 2012; 108: 410-411.
• 7 Aradi D, Kuliczkowski W, Atar D. et al. Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel. Thromb Haemost 2012; 107: 338-345.
• 8 Serebruany VL. Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified. Thromb Haemost 2011; 105: 752-759.
• 9 Ohman EM, Roe MT. Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5). Thromb Haemost 2011; 105: 763-710.
• 10 MacFadyen J, Jackson S. Differentiating hemostasis from thrombosis for therapeutic benefit. Thromb Haemost 2013; 110: 859-867.
• 11 Ungerer M, Münch G. Novel antiplatelet drugs in clinical development. Thromb Haemost 2013; 110: 868-875.
• 12 Geisler T, Gawaz M. Genetic variation of platelet function and pharmacology: Update of current knowledge. Thromb Haemost 2013; 110: 876-887.
• 13 Langer HF, Haubner R, Pichler BJ. et al. Radionuclide imaging: a molecular key to the atherosclerotic plaque. J Am Coll Cardiol 2008; 52: 1-12.
• 14 Libby P, Ridker PM, Hansson GK. Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54: 2129-2138.
• 15 Langer HF, Choi EY, Zhou H. et al. Platelets Contribute to the Pathogenesis of Experimental Autoimmune Encephalomyelitis. Circ Res 2012; 110: 1202-1210.
• 16 Langer H, Chavakis T. Platelets and neurovascular inflammation. Thromb Haemost 2013; 110: 888-893.
• 17 Karshovska E, Weber C, von Hundelshausen P. Platelet chemokines in health and disease. Thromb Haemost 2013; 110: 894-902.
• 18 Seizer P, May A. Platelets and matrix metalloproteinases. Thromb Haemost 2013; 110: 903-909.
• 19 Strüßmann T, Tillmann S, Wirtz T. et al. Platelets are a previously unrecognized source of MIF. Thromb Haemost 2013; 110: 1004-1013.
• 20 Verschoor A, Langer H. Crosstalk between platelets and the complement system in immune protection and disease. Thromb Haemost 2013; 110: 919-919.
• 21 Krämer B, Weyrich A, Lindemann S. Protein degradation systems in platelets. Thromb Haemost 2013; 110: 920-924.
• 22 Lang F, Muenzer P, Gawaz M. et al. Regulation of STIM1/Orai1-dependent Ca2+ Signaling in Platelets. Thromb Haemost 2013; 110: 925-930.